A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma

A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma Timothy Cooley, David Henry, Margaret Tonda, Steven Sun, Martin O'Connell, Wayne Rackoff Oncologist 2007; 12: 114-123 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Discuss the current prevalence of Kaposi's sarcoma complicating HIV infection. Describe the impact of highly active antiretroviral therapy (HAART) on Kaposi's sarcoma complicating HIV infection. Prioritize treatment options for Kaposi's sarcoma complicating HIV infection. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 16, 2007 Most Recent Review: Jan. 16, 2007* Most Recent Update: Jan. 16, 2007 Date Credit Expires: Jan. 16, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course